Summary & Overview
CPT 81506: Diabetes Biomarker Panel with Algorithmic Risk Score
CPT code 81506 designates a laboratory service that runs seven biochemical assays linked to diabetes and uses an algorithm to integrate assay results with patient data to report a patient risk score. This code captures combined analytic and reporting activity that supports risk stratification for diabetes-related outcomes and clinical decision-making. Nationally, such molecular/algorithmic testing is increasingly relevant as payers and providers seek quantifiable risk measures to guide population health management and personalized care.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find coverage and coding context for how algorithmic laboratory reports are billed, typical sites of service and clinical roles involved, and the practical implications for claims submission and payer review. The publication summarizes common modifiers associated with laboratory and professional components, outlines where to find additional coding guidance, and situates CPT 81506 within broader trends in lab-developed tests and clinical risk modeling.
Content emphasizes billing and policy relevance rather than clinical recommendations, offering a concise reference for billing staff, laboratory directors, and payers evaluating claims for algorithm-driven diabetes biomarker panels.
Billing Code Overview
CPT code 81506 describes a laboratory-based diagnostic service in which the laboratory analyst performs the technical testing for seven biochemical assays related to diabetes and executes an algorithmic analysis that combines those test results with patient data to produce a patient risk score.
-
Service type: Laboratory diagnostic testing with algorithmic risk-score reporting
-
Typical site of service: Clinical laboratory or reference laboratory setting where biochemical assays and computational analysis are performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with type 2 diabetes mellitus presents for routine management and risk stratification. The clinician orders a laboratory panel that includes seven biochemical assays (such as hemoglobin A1c, fasting glucose, C-peptide, insulin, lipid markers, serum creatinine, and urinary albumin) processed by a clinical laboratory. The lab analyst performs the technical assays and inputs patient demographic and clinical data into a validated algorithmic analytic platform which calculates and reports a composite patient risk score for diabetes-related complications. Results are delivered to the ordering clinician and integrated into the electronic health record to inform longitudinal care planning and potential referral to endocrinology, nephrology, or cardiology.
Typical site of service: Clinical reference laboratory or hospital laboratory with a certified clinical laboratory improvement amendments (CLIA) waiver or appropriate CLIA certification. The specimen is collected in an outpatient clinic, physician office, or hospital outpatient phlebotomy service and shipped to the performing laboratory.
Typical patient scenario: An outpatient visit for diabetes follow-up where the clinician documents medication adherence concerns, recent weight change, and a need to stratify risk for microvascular and macrovascular complications. The clinician orders the composite biomarker panel with algorithmic analysis to guide intensity of monitoring and referrals. The laboratory performs the seven assays, runs the algorithm, and returns a calculated patient risk score with interpretive comments to the ordering provider.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|